Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare ltd - clarithromycin - prolonged-release tablet - 500 milligram(s) - macrolides; clarithromycin

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - clarithromycin - prolonged-release tablet - 500 milligram(s) - macrolides; clarithromycin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - metformin hydrochloride - modified-release tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - metformin hydrochloride - modified-release tablet - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - metformin hydrochloride - modified-release tablet - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - metformin hydrochloride - modified-release tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - metformin hydrochloride - modified-release tablet - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - clarithromycin - modified-release tablet - 500mg

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - fostemsavir trometamol, quantity: 724.56 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; hyprolose; hypromellose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - rukobia is indicated in combination with other antiretroviral agents for the treatment of heavily treatment-experienced adults with multidrug-resistant human immunodeficiency virus-1 (hiv-1) infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations (see section 5.1 pharmacodynamic properties, clinical trials).

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare ltd - diclofenac sodium; misoprostol - modified-release tablet - 50 mg/200 microgram(s) - acetic acid derivatives and related substances; diclofenac, combinations